Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

被引：0
作者：
Hai-Liang Zhang
Xi-Nan Sheng
Xue-Song Li
Hong-Kai Wang
Zhi-Hong Chi
Zhi-Song He
Ding-Wei Ye
Jun Guo
机构：
[1] Department of Urology,Department of Oncology
[2] Fudan University Shanghai Cancer Center,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma
[3] Shanghai Medical College,Department of Urology, Peking University First Hospital, Institute of Urology, National Urological Cancer Center
[4] Fudan University,undefined
[5] Peking University Cancer Hospital & Institute,undefined
[6] Peking University,undefined
来源：
BMC Cancer | / 17卷
关键词：
Metastatic renal cell carcinoma; Sorafenib; Sunitinib; Prognosis; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 122 条
  • [1] Wersall PJ(2005)Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma Radiother Oncol 77 88-95
  • [2] Blomgren H(2015)Cancer statistics, 2015 CA Cancer J Clin 65 5-29
  • [3] Lax I(2007)Targeted drugs for metastatic renal cell carcinoma Lancet 370 2071-2073
  • [4] Siegel RL(2007)AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103-2111
  • [5] Miller KD(1998)Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma N Engl J Med 338 1272-1278
  • [6] Jemal A(2007)Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125-134
  • [7] Motzer RJ(2014)Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma J Clin Oncol 32 760-767
  • [8] Basch E(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma Engl J Med 356 115-124
  • [9] Escudier B(2013)A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update Eur J Cancer 49 1287-1296
  • [10] Pluzanska A(2010)RECORD‐1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 4256-65
12345678910